Evidence map›Paper›PMID 34144245›Full record

ArticleJournal of stomatology, oral and maxillofacial surgery2022

Could treatment with botulinum toxin protect against subsequent infection with COVID-19?

D Batifol, P J Finiels, S Galmiche, P Jammet, M de Boutray

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of stomatology, oral and maxillofacial surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Harnessing the Natural Toxic Metabolites in COVID-19.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

D BatifolMaxillofacial Surgery Department, Montpellier University Hospital Gui de Chauliac, Montpellier, France. Electronic address: dominique.batifol@dbmail.com.
P J FinielsDepartment of Orthopedics, Traumatology and Spine Neurosurgery, Alès General Hospital, Alès, France.
S GalmicheMaxillofacial Surgery Department, Montpellier University Hospital Gui de Chauliac, Montpellier, France.
P JammetMaxillofacial Surgery Department, Montpellier University Hospital Gui de Chauliac, Montpellier, France.
M de BoutrayMaxillofacial Surgery Department, Montpellier University Hospital Gui de Chauliac, Montpellier, France.
Université de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report comparative results, over three months, of the impact of SARS-CoV2 in our patients injected with botulinum toxin for functional purposes, compared to the general population. Botulinum neurotoxin type A (BoNT/A) is known to block acetylcholine (ACh) as well as many other neuroreceptors and neuromodulators. The recent mention of a potential protective effect of nicotine in COVID 19, by blocking ACh, attracted our attention and guided the present study. Our results show a significant difference between the number of infected individuals in the general population and the number of patients injected with BoNT/A who showed signs of COVID 19.

Indexed as

Botulinum Toxins, Type ACOVID-19HumansRNA, ViralSARS-CoV-2Botulinum Toxins, Type ARNA, ViralAcetylcholine blockingBotulinum toxinCOVID-19

Identifiers

PMID34144245
PMCPMC8205559
OpenAlexW3168992047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.